As India’s assisted reproductive technology sector grows rapidly due to changing family patterns and increased awareness, insurance coverage for fertility treatments remains limited, leaving many patients to bear high costs alone, with potential for future policy shifts on the horizon.
India’s fertility-treatment market is expanding quickly as changing family patterns and rising awareness drive more couples towards assisted reproduction, but the financial safety net has not kept pace. The sector now includes more than 4,400 registered assisted reproductive technology clinics, yet standard health insurance in India still generally excludes in-vitro fertilisation and related procedures, leaving patients to absorb most of the cost themselves, according to the lead report.
The price tag varies sharply depending on the clinic, the city and the treatment plan. Iswarya Fertility says a standard IVF cycle in 2026 can cost between ₹99,000 and ₹1.2 lakh, while SheIVF places the range for a basic cycle using a couple’s own eggs and sperm at ₹1.3 lakh to ₹2.8 lakh. Shifam Health gives a lower estimate of ₹60,000 to ₹80,000 before medicines, accommodation and travel. The difference reflects what is included: medicines, scans, embryo transfer, laboratory work and pregnancy tests are often only part of the bill, while procedures such as ICSI, embryo freezing, storage and genetic testing can push costs higher.
That financial uncertainty helps explain why insurers have been slow to move. Fertility treatment is difficult to price because outcomes are unpredictable, and insurers also worry about adverse selection, where people already planning treatment are the most likely to buy cover. As a result, coverage is usually limited to employer schemes or bespoke add-ons rather than standard retail policies. IVFHelp says only about 5% of health plans offer some fertility cover, often as a rider, although it also notes that the Employees’ State Insurance Corporation provides IVF at designated hospitals for eligible workers.
There are signs of change, albeit narrowly. The Indian Banks’ Association medical insurance scheme is due to introduce a ₹2 lakh infertility-treatment limit from November 1, 2026, but that benefit will apply only to a specific group of policyholders. For most patients, the practical advice remains the same: read the exclusions carefully and ask for a fully itemised estimate before starting treatment, because even policies that do offer some fertility support may not pay for ICSI, freezing, storage or genetic tests. Whether the broader market eventually develops actuarially priced fertility products will determine if IVF remains largely self-funded or becomes more widely insurable.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
